NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3567.40 19.10 (0.54%)

207.5K NSE+BSE Volume

NSE 18 Sep, 2025 3:31 PM (IST)

120,737

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

26 May 2022

3567.40

0.54%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

ICICI Direct

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3318.0

Torrent Pharmaceuticals Ltd.

26 May 2022

3567.40

0.54%

V-Mart Ltd.

Buy: Torrent Pharmaceuticals Ltd.

ICICI Direct

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

26 May 2022

3567.40

0.54%

TORRENT PHARMACEUTIC

Buy: Torrent Pharmaceuticals Ltd.

Target

Prabhudas Lilladhar

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

26 May 2022

3567.40

0.54%

India/Brazil outshine; decline in the US sales growth ceases

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3318.0

Torrent Pharmaceuticals Ltd.

07 Feb 2022

3567.40

0.54%

TORRENT PHARMA

Buy: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

27 Jan 2022

3567.40

0.54%

TORRENT PHARMACEUTIC

Buy: Torrent Pharmaceuticals Ltd.

Prabhudas Lilladhar

Torrent Pharma's (TRP) Q3FY22 performance was disappointing however we believe profitability/margins to normalize from FY23, aided by price hike in branded generic business and current cost escalation temporary. TRP's high exposure to branded generic business (~65-70% of total revenues) and chronic therapies provides comfort. The timely resolution of plants will pickup revenue growth in US and benefit operating leverage, going ahead. We expect 18% EPS CAGR over FY21-24E. We have cut our FY22E EPS by 6%...

Sharekhan decreased Buy price target of Torrent Pharmaceuticals Ltd. to 4024.0 on 29 Aug, 2025.

Torrent Pharmaceuticals Ltd.

26 Jan 2022

3567.40

0.54%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3318.0

Torrent Pharmaceuticals Ltd.

26 Jan 2022

3567.40

0.54%

US drags 3QFY22 earnings; inspections key to a revival

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

TRP's 3QFY22 performance missed our estimate. The US Generics business remains the major drag on overall performance, with a lack of new approvals and a steep price erosion in the base business. Domestic Formulation (DF) remains in good stead, with healthy better-than-industry performance. The management intends to add medical representatives (MRs) to further strengthen the growth outlook in the DF segment. We reduce our FY22E/FY23E/FY24E EPS estimate by ~13%/7.5%/3.5% to factor in: a) a sharp reduction in the price realization of certain products...